STAT

‘There’s no such thing as anonymity’: With consumer DNA tests, sperm banks reconsider long-held promises to donors

For generations, it was a basic tenet of donating sperm: Clinics could forever protect their clients’ identities. But, increasingly, donor anonymity is dead.

For generations, it was a basic tenet of donating sperm: Clinics could forever protect their clients’ identities.

But, increasingly, donor anonymity is dead.

The rise of consumer genetic tests — which allow people to connect with relatives they never knew they had, including some who never intended to be found in the first place — is forcing sperm donation clinics to confront the fact that it is now virtually impossible to guarantee anonymity to their clients. Instead, sites like 23andMe and Ancestry.com are giving customers the genetic clues they need to identify biological parents on their own.

That, clinics and outside experts say, has forced a reckoning for the industry. Many clinics say they have revised their policies — not to eliminate “anonymous” donations, but to make clear that the term only means they will not share donor information. Others are gravitating toward “open ID” donor systems, in which donors are told that offspring could connect with them when they turn 18 — or sooner — if both parties agree to it.

And in at least one case, a clinic has sought to draw a line in the sand, ordering a woman to cease and desist efforts to contact

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks